Cardiovascular Bioengineering (CVBE) Symposium - 2019

心血管生物工程 (CVBE) 研讨会 - 2019

• 批准号: 9763289
• 负责人: JOEL L BERRY
• 金额: $ 1.26万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-03-01 至 2020-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9763289
• 关键词: Alabama; Anniversary; Area; Australia; Award; Berry; Biological Sciences; Biomedical Engineering; Cardiac; Cardiac development; Cardiovascular system; Cell Maturation; Cell Therapy; Cells; Collaborations; Communities; Engineering; Ensure; Equilibrium; Functional disorder; Future; Genes; Goals; Grant; Heart Diseases; Heart failure; Hip region structure; Individual; Learning; Life; Medical Research; Metabolic; MicroRNAs; Minority; Mitochondria; Molecular; National Heart, Lung, and Blood Institute; Pluripotent Stem Cells; Regenerative Medicine; Request for Proposals; Research; Research Personnel; Science; Scientist; Stem cells; Tissue Engineering; Travel; Underrepresented Minority; United States National Institutes of Health; Universities; Videotape; Work; cardiac tissue engineering; career; combat; cost; design; epigenetic regulation; exosome; experience; induced pluripotent stem cell; lectures; medical specialties; meetings; minority investigator; molecular targeted therapies; next generation; novel; novel therapeutics; outreach; posters; programs; recruit; stem cell differentiation; success; symposium

Project Summary This is a new application to support efforts to increase involvement of trainees and junior scientists for the 2019 Cardiovascular Bioengineering Symposium (CVBE) to be held on the campus of The University of Sydney, Australia. This will be the 4th Anniversary of the Symposium. The uniqueness of the CVBE symposium lies in its combination of top researchers in cardiovascular bioengineering, trainees, junior investigators, and underrepresented minorities. The symposium will provide a forum for trainees, junior and minority investigators to interact with world's leading scientists as they present their work. This work reflects the convergence of life sciences and engineering in the areas of gene editing, induced pluripotent stem cells, and cardiac stem cells in the context of heart failure as well general topics in cardiovascular bioengineering. This conference has previously been held separately from (but in conjunction with) the NIH NHLBI progenitor cell translational consortium (NIH PCTC) for the past 3 years1, 2, 3, 4 by The University of Alabama at Birmingham (UAB). The meeting became an annual public symposium in 2016, and since then, this conference has been recognized as a unique public and recurring scientific symposium of stem cell and cardiovascular bioengineering. The conference in recent 2 years has added translational topics as well as the “bread and butter” of this meeting, which is basic stem cell bioengineering, molecular cardiovascular research, and tissue engineering. The conference has attracted the world's leading scientists in field of cardiac stem cells.1, 2, 3, 4 The original conference topics started with tissue engineering, hiPS cells, cardiac development, and recent two years has grown to include exosome, microRNAs, mitochondria, cardiac gene and cardiac cell therapy. The attendance of this conference has climbed and, in 2018, we had attendance of over 200. As in past years, the conference will be held in late February/early March, and this year, will be held March 1-2 at The University of Sydney. The planned agenda represents an ambitious, fast-paced meeting with 8 sessions in 1.5 days including the Keynote lecture. Young cardiovascular scientists will be highlighted through invited talks at each session. Organizers of this meeting are Drs. Jianyi (Jay) Zhang (UAB), James Chong (U of Sydney), Gangjian Qin (UAB), and Joel Berry (UAB). This proposal requests $10,000, and as we have done over the last several years, the support will be used towards the cost of trainee travel, trainee poster session awards, meeting supplies, and support for videotaping all sessions.

项目摘要 这是一个新的申请，以支持增加2019年受训者和初级科学家参与的努力 心血管生物工程研讨会（CVBE）将于悉尼大学校园举行 澳大利亚。这将是研讨会成立4周年。 CVBE研讨会的独特性在于它的 心血管生物工程，学员，初级研究人员和 代表性不足的少数民族。研讨会将为培训，初级和少数族裔调查员提供论坛 在展示工作时与世界领先的科学家互动。这项工作反映了生活的融合 基因编辑区域，诱导多能干细胞和心脏干细胞的科学和工程 心力衰竭和心血管生物工程中的一般主题的背景。这次会议有 以前被与NIH NHLBI祖细胞平移（但与之结合）分开（但与之结合） 过去3年的财团（NIH PCTC）1、2、3、4由阿拉巴马大学伯明翰大学（UAB）。 会议成为2016年的年度公开研讨会，从那以后，该会议被认为是 干细胞和心血管生物工程的独特公开和经常性的科学研讨会。 最近两年的会议增加了翻译主题以及这次会议的“面包和黄油”， 这是基本的干细胞生物工程，分子心血管研究和组织工程。 会议吸引了世界干细胞领域的世界领先科学家。1、2、3、4原始科学家 会议主题始于组织工程，臀部细胞，心脏发展和最近两年 成长为包括外泌体，microRNA，线粒体，心脏基因和心脏细胞疗法。出席 这次会议已经攀升，在2018年，我们参加了200多次。与过去的几年一样，会议将 将于2月下旬/3月初举行，今年将于3月1日至2日在悉尼大学举行。这 计划中的Agernda代表了一次雄心勃勃的快节奏会议，在1.5天内举行了8次会议，包括主题演讲 演讲。年轻的心血管科学家将通过每次会议的邀请演讲来强调。组织者 这次会议是博士。 Jianyi（Jay）Zhang（UAB），James Chong（悉尼U），Gangjian Qin（UAB）和Joel 贝里（UAB）。该提案要求$ 10,000，正如我们在过去几年中所做的那样，支持 将用于学员旅行的费用，学员海报会议奖，会议用品以及 支持录像所有会议。